<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204118">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432042</url>
  </required_header>
  <id_info>
    <org_study_id>V221-035</org_study_id>
    <secondary_id>X06-MMRV-302</secondary_id>
    <nct_id>NCT00432042</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly</brief_title>
  <official_title>An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To demonstrate that ProQuad® can be administered concomitantly with a booster dose of
           Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the
           antibody response rates to measles, mumps, rubella, varicella, hepatitis B and
           Haemophilus influenzae type b; or to the 3 pertussis antibody titres measured at 42
           days following vaccination.

      Secondary Objectives:

        -  To describe the antibody titres and the antibody response rates to measles, mumps,
           rubella, varicella, diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and
           Haemophilus influenzae type b as measured at 42 days following vaccination by an
           Infanrix® hexa primary series schedule and all data are pooled.

        -  To evaluate the safety profile of ProQuad® when administered concomitantly with a
           booster dose of Infanrix® hexa by an Infanrix® hexa primary series schedule and all
           data are pooled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <enrollment type="Anticipated">960</enrollment>
  <condition>Varicella</condition>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad® and Infanrix® hexa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects of either gender

          -  Aged 12 to 23 months

          -  No clinical history of measles, mumps, rubella, varicella and zoster

          -  For Italy: Primary vaccination with the combined diphtheria, tetanus, pertussis,
             hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine Infanrix® hexa
             as a 2-dose schedule, with receipt of the second dose ≥ 6 months prior to inclusion

          -  For Germany: Primary vaccination with the combined diphtheria, tetanus, pertussis,
             hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine Infanrix® hexa
             as a 3-dose schedule, with receipt of the third dose ≥ 6 months prior to inclusion

          -  Consent form signed by parent(s) according to local regulations or by the legal
             representative properly informed about the study

          -  Parent(s)/legal representative able to understand the protocol requirements and to
             fill in the Diary Card.

        Exclusion Criteria:

          -  Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in
             any combination

          -  Any recent (&lt;= 30 days) exposure to measles, mumps, rubella, varicella and/or zoster

          -  Receipt of any other diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis
             and/or Haemophilus influenzae type b containing vaccine (either alone or in any
             combination) than Infanrix® hexa

          -  Any recent (&lt;= 3 days) history of febrile illness

          -  Any severe chronic disease

          -  Active untreated tuberculosis

          -  Known personal history of encephalopathy, seizure disorder or progressive, evolving
             or unstable neurological condition

          -  Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant
             neoplasms affecting the haematopoietic or lymphatic systems

          -  Any severe thrombocytopenia or any other coagulation disorder that would
             contraindicate intramuscular injection

          -  Prior known sensitivity/allergy to any component of the vaccines including neomycin,
             sorbitol or gelatin

          -  Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed
             immunity

          -  Any recent (&lt;= 2 days) tuberculin test or scheduled tuberculin test through Visit 2

          -  Any previous (&lt;= 150 days) receipt of immune serum globulin or any blood-derived
             products or scheduled to be administered through Visit 2

          -  Any recent (&lt;= 30 days) receipt of an inactivated or a live non-study vaccine or
             scheduled non-study vaccination through Visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Fiquet, MD</last_name>
    <role>Study Director</role>
    <affiliation>SPMSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alsfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Saulgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Sobernheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Säckingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birkenfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bramsche</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bretten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brunsbüttel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Datteln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detmold</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Espelkamp</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ettenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Friedrichshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gerolstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifhorn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heilbronn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herbolzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kehl</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lauffen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neustadt a.d. Aisch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nidderau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberkirch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pegnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rodorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwieberdingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwäbisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Traunreut</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veitshöchheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wanzleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Welzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wildeshausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwiesel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiavari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Latisana</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>February 5, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mumps and Rubella</keyword>
  <keyword>Haemophilus influenzae type b (Infanrix® hexa)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
